Edwards Lifesciences
EW
$85.52
+1.36%
Edwards Lifesciences Corp is a global medical device company that designs, manufactures, and markets devices for structural heart disease, with a portfolio spanning surgical tissue heart valves, transcatheter aortic valve replacement (TAVR), and transcatheter mitral and tricuspid therapies. Spun off from Baxter International in 2000, the firm has established itself as the undisputed leader in the transcatheter heart valve market, deriving roughly 60% of sales from outside the US and employing approximately 16,000 people. The current investor narrative centers on a powerful regulatory catalyst: a US agency proposal to broaden and simplify Medicare coverage for TAVR procedures, which could significantly expand the addressable patient population and accelerate procedure volumes for the company's core franchise. This tailwind is reinforced by recent quarterly results that beat expectations and prompted management to raise guidance, driven by robust demand for heart valve therapies, though the stock's recent underperformance relative to the broader market suggests investors are weighing near-term execution risks against the long-term structural growth story.…
EW
Edwards Lifesciences
$85.52
Related headlines
Investment Opinion: Should I buy EW Today?
Rating: Buy. Edwards Lifesciences offers a compelling risk/reward profile for long-term investors, anchored by its dominant position in the transcatheter heart valve market, accelerating revenue growth of 16.7% YoY, and a potential Medicare coverage expansion that could significantly enlarge the addressable patient population. The analyst consensus is Buy with an average target price of $100.96, implying 19.7% upside from the current price of $84.37, and even the lowest target of $84.00 is essentially at the current price, suggesting limited downside according to the analyst community.
The supporting evidence is robust: revenue grew 16.7% YoY in Q1 2026 to $1.649 billion, the strongest rate in five quarters; gross margin remains exceptionally high at 78.2%; operating margin improved to 31.2% from 23.6% in Q4 2025; and the balance sheet is fortress-like with a debt-to-equity of 0.068 and $2.448 billion in cash. The forward PE of 25.0x is reasonable relative to expected EPS growth of 20-25%, implying a PEG of approximately 1.0-1.25, which is fair for a high-quality medical device leader. The trailing PE of 46.3x is elevated, but the forward multiple better reflects normalized earnings power.
The biggest risks that could invalidate the thesis include: (1) a delay or dilution of the Medicare coverage expansion, which would remove a key catalyst; (2) revenue growth decelerating below 10% due to competitive pressures or slower TAVR adoption; and (3) further multiple compression if the market rotates away from premium-valued healthcare stocks. The rating would upgrade to a strong Buy if the Medicare proposal is finalized and procedure volumes accelerate, or downgrade to Hold if revenue growth falls below 12% or if free cash flow remains negative for multiple quarters. Relative to its own history, the price-to-book ratio of 4.82x is near the lower end of its five-year range (4.1x to 13.9x), suggesting the stock is undervalued on a book value basis, though the premium PE and EV/EBITDA multiples indicate the market is pricing in significant growth. Overall, EW appears fairly valued to slightly undervalued given its growth prospects and dominant market position.
Sign up to view all
EW 12-Month Price Forecast
Edwards Lifesciences presents a compelling growth story with a dominant TAVR franchise, accelerating revenue growth, and a potential Medicare coverage expansion that could significantly expand the addressable market. The company's exceptional gross margins (78.2%) and improving operating margins (31.2%) demonstrate strong pricing power and operating leverage. The analyst community remains overwhelmingly bullish, with a Buy consensus and an average target price of $100.96, implying 19.7% upside. However, the premium valuation (46.3x trailing PE, 33.3x EV/EBITDA) and recent price weakness (-9.33% in one month) suggest that the market is pricing in significant growth expectations, leaving little room for error. I would upgrade to high confidence if the Medicare coverage expansion is finalized and procedure volumes accelerate, or downgrade to neutral if revenue growth decelerates below 12% or if free cash flow remains negative for multiple quarters.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $100.96 and implied upside of +18.1% versus the current price.
Average Target
$100.96
0 analysts
Implied Upside
+18.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
EW is covered by 26 analysts, with a consensus recommendation of "Buy" and a recommendation mean of 1.62 (on a scale where 1 is Strong Buy and 5 is Strong Sell). The average target price is $100.96, which implies a +19.7% upside from the current price of $84.37. The consensus is decidedly bullish, with the majority of analysts maintaining positive ratings. Recent institutional ratings show a preponderance of Buy/Outperform ratings from firms such as Mizuho, RBC Capital, Citigroup, Evercore ISI, BTIG, and TD Cowen, with only a few Hold ratings from Truist Securities and Canaccord Genuity. This distribution suggests that the analyst community remains confident in the company's growth prospects despite the recent stock price weakness.
The target price range spans from a low of $84.00 to a high of $110.00, a spread of $26.00, or approximately 31% of the current price. The low target of $84.00 is essentially at the current price, implying that even the most bearish analyst sees the stock as fairly valued with no downside, while the high target of $110.00 assumes a +30.4% upside. The high target likely prices in successful expansion of TAVR indications, strong adoption of TMTT products, and continued margin expansion. The low target may reflect concerns about competitive pressures, slower-than-expected procedure growth, or macroeconomic headwinds. The relatively wide spread indicates moderate uncertainty, but the fact that the low target is at the current price suggests limited downside according to analysts. The estimated EPS average of $4.62 for the forward year, with a range of $4.48 to $4.76, supports the earnings growth narrative. Overall, the analyst community leans bullish, and the recent pullback may present an attractive entry point for long-term investors.
Drowning in data?
Find the real signal!
Bulls vs Bears: EW Investment Factors
The bull case rests on Edwards' dominant TAVR franchise, accelerating revenue growth of 16.7% YoY, fortress balance sheet, and a potential Medicare coverage expansion that could significantly enlarge the addressable market. The bear case centers on the stock's premium valuation (46.3x trailing PE), recent price weakness (-9.33% in one month), negative Q1 free cash flow, and heavy reliance on a single product category. Currently, the bull evidence appears stronger given the company's consistent beat-and-raise quarters, exceptional 78.2% gross margins, and overwhelming analyst support (Buy consensus, 19.7% upside to average target). The single most important tension is whether the Medicare coverage expansion materializes and translates into accelerated procedure volumes—if it does, the premium valuation is justified; if it stalls or is delayed, the stock could face further multiple compression.
Bullish
- TAVR Medicare Coverage Expansion: A U.S. agency proposal to broaden and simplify Medicare coverage for TAVR procedures could significantly expand the addressable patient population. As the undisputed TAVR market leader, Edwards is best positioned to capture this incremental procedure volume, which would accelerate revenue growth beyond the current 16.7% YoY pace.
- Strong Revenue Growth and Beat-and-Raise: Q1 2026 revenue grew 16.7% YoY to $1.649 billion, the strongest growth rate in the last five quarters. Management raised guidance following the beat, and the consistent sequential progression from $1.413B to $1.649B demonstrates durable top-line momentum.
- Fortress Balance Sheet with Minimal Debt: Debt-to-equity is just 0.068 and the current ratio is 3.72, providing substantial financial flexibility. With $2.448 billion in cash and $1.09 billion in trailing free cash flow, Edwards can fund R&D, acquisitions, and share repurchases without financial strain.
- Exceptional Gross Margins and Operating Leverage: Gross margin remains exceptionally high at 78.2%, reflecting strong pricing power and a favorable product mix. Operating margin improved to 31.2% in Q1 2026 from 23.6% in Q4 2025, indicating effective cost management and operating leverage.
Bearish
- Premium Valuation vs. Sector: The trailing PE of 46.3x and EV/EBITDA of 33.3x are well above the medical device industry average PE of 20-30x. This premium leaves little room for execution missteps and increases vulnerability to multiple compression if growth decelerates.
- Recent Price Weakness and Underperformance: EW has declined 9.33% over the past month and underperformed the S&P 500 by 8.27% over the same period. The stock is down 7.1% in just seven trading sessions from September 2 to September 11, signaling accelerating selling pressure and loss of momentum.
- Working Capital Drain and Negative Q1 FCF: Q1 2026 free cash flow was negative $21.1 million due to a $501.5 million working capital outflow. Operating cash flow fell to $43.8 million from $573.7 million in Q3 2025, raising concerns about cash conversion and earnings quality.
- Earnings Volatility and One-Time Items: Trailing EPS of $0.02 is distorted by one-time items, including a $279.9 million other expense in Q4 2025 that caused net income to plunge to $91.2 million. This earnings volatility complicates valuation and may deter risk-averse investors.
EW Technical Analysis
EW is in a broad recovery phase within a wider range, with a 1-year price change of +8.15% that masks significant intra-year volatility. The stock currently trades at $84.37, which sits at approximately 50.4% of its 52-week range (low of $72.30, high of $96.29), placing it squarely in the middle of its annual band. This neutral positioning suggests neither an overextended momentum trade nor a deeply discounted value opportunity, but rather a market that is awaiting clearer directional catalysts. The 52-week high of $96.29 was set in early July 2026, and the subsequent pullback has left the stock consolidating in the mid-$80s.
Recent momentum has deteriorated sharply, with a 1-month decline of -9.33% contrasting starkly with the positive 1-year gain of +8.15%. Over the past three months, the stock is down -0.87%, indicating that the intermediate-term trend has flattened after a strong first-half rally. This divergence—positive annual returns but negative short-term performance—signals a loss of upward momentum and potential mean reversion, especially as the stock has fallen from its July peak. The relative strength versus SPY is notably weak: -8.27% over 1 month and -8.07% over 1 year, meaning EW has underperformed the S&P 500 by a wide margin. The recent decline from $90.82 on September 2 to $84.37 on September 11 represents a -7.1% drop in just seven trading sessions, underscoring accelerating selling pressure.
Key technical levels are well-defined: support rests at the 52-week low of $72.30, while resistance is anchored at the 52-week high of $96.29. A breakdown below the $80 psychological area could open the door to a retest of the $72.30 low, whereas a breakout above $96.29 would signal a new leg higher and likely attract momentum buyers. The stock's beta of 0.852 indicates it is roughly 15% less volatile than the broader market, which may appeal to risk-averse investors but also means it could lag in a sharp market rally. The maximum drawdown of -13.19% over the period reflects moderate risk, and the current price is about 12.4% below the 52-week high, suggesting room for recovery if catalysts materialize.
Beta
0.85
0.85x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+10.2%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -6.6% | -2.0% |
| 3m | -3.5% | +1.4% |
| 6m | +3.5% | +15.0% |
| 1y | +10.2% | +15.7% |
| ytd | +0.2% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
EW's revenue trajectory remains solidly growth-oriented, with the most recent quarter (Q1 2026) delivering $1.649 billion in revenue, a +16.7% year-over-year increase from $1.413 billion in Q1 2025. This acceleration is notable: Q4 2025 revenue was $1.570 billion, up from $1.386 billion in Q4 2024 (+13.3% YoY), and Q3 2025 revenue of $1.553 billion grew from $1.354 billion (+14.7% YoY). The sequential progression from $1.413B to $1.532B to $1.553B to $1.570B to $1.649B over the last five quarters demonstrates consistent top-line expansion, with the latest quarter showing the strongest YoY growth rate in the period. Segment data reveals that Transcatheter Heart Valves (THV) generated $1.197 billion, or 72.6% of total revenue, while Transcatheter Mitral and Tricuspid Therapies (TMTT) contributed $175.1 million, representing a smaller but strategically important early-stage growth driver. The sustained double-digit growth implies that the investment case rests on continued adoption of transcatheter therapies and geographic expansion.
Profitability is robust, with Q1 2026 net income of $380.7 million and a net margin of 23.1%, up from 21.5% in Q2 2025 and 18.7% in Q3 2025, though below the 25.3% recorded in Q1 2025. Gross margin remains exceptionally high at 78.2% in Q1 2026, consistent with the 77.6%–78.7% range over the past eight quarters, reflecting strong pricing power and a favorable product mix. Operating margin stood at 31.2% in Q1 2026, a significant improvement from 23.6% in Q4 2025 and 27.4% in Q3 2025, indicating effective cost management and operating leverage. The company's EBITDA of $499.9 million in Q1 2026 translates to a 30.3% EBITDA margin, healthy for the medical device industry. The Q4 2025 net income dip to $91.2 million (5.8% net margin) was an anomaly likely due to one-time items, as the trailing twelve-month net margin remains a solid 17.7%.
The balance sheet is fortress-like, with a debt-to-equity ratio of just 0.068 and a current ratio of 3.72, indicating minimal leverage and ample liquidity. Cash and equivalents stood at $2.448 billion at the end of Q1 2026, providing substantial firepower for R&D, acquisitions, and share repurchases. Free cash flow on a trailing twelve-month basis is $1.090 billion, though Q1 2026 free cash flow was negative $21.1 million due to a $501.5 million working capital outflow and $64.9 million in capital expenditures. Operating cash flow in Q1 2026 was only $43.8 million, a sharp decline from $573.7 million in Q3 2025 and $450.9 million in Q4 2025, largely attributable to changes in working capital. Return on equity is 10.4%, and return on assets is 8.4%, which are respectable but not exceptional, partly due to the company's large cash position. The company repurchased $521.8 million of stock in Q1 2026, signaling confidence in its financial position and commitment to shareholder returns.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Because EW is profitable with positive net income of $380.7 million in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE stands at 46.3x, while the forward PE is 25.0x, implying a significant gap that reflects the market's expectation of substantial earnings growth. The forward PE is based on estimated EPS of $4.62, which is more than double the trailing EPS of $0.02 (distorted by one-time items), indicating that analysts expect earnings to normalize and grow robustly. This wide spread between trailing and forward multiples suggests the market is pricing in a strong earnings recovery, likely driven by revenue growth and margin expansion.
Compared to the broader medical device sector, EW's valuation appears rich. The PS ratio is 8.22x, and the EV/EBITDA is 33.3x, both of which are premium multiples. The industry average PE for medical devices typically ranges between 20x and 30x, so EW's forward PE of 25.0x is roughly in line with or slightly below the higher end of that range, but its trailing PE of 46.3x is a significant premium. The price-to-book ratio of 4.82x is also elevated relative to the sector. However, the premium is justified by EW's superior growth profile (+16.7% YoY revenue growth), industry-leading gross margins (78.1%), and dominant market position in TAVR. The PEG ratio is negative (-0.63) due to the trailing earnings distortion, but on a forward basis, the PEG would be more meaningful; using the forward PE of 25.0x and expected EPS growth of roughly 20-25%, the PEG would be approximately 1.0-1.25, suggesting a fair valuation relative to growth.
Historically, EW's valuation has compressed significantly. The trailing PE of 46.3x is well below the 133.2x recorded in Q4 2025 and the 30.3x in Q1 2026, but the Q1 2026 figure was based on a different earnings base. Looking at the PS ratio, the current 8.22x is dramatically lower than the 28.1x in Q1 2026 and the 31.5x in Q4 2025, though those periods had distorted earnings. Over the past three years, the PS ratio has ranged from a low of 28x to a high of 60x, so the current 8.22x appears anomalously low, likely due to the recent stock price decline and revenue growth. The price-to-book ratio of 4.82x is near the lower end of its historical range (4.1x to 13.9x over the past five years), suggesting the stock is trading at a discount to its own history on a book value basis. This could indicate a value opportunity if fundamentals remain intact, or it could reflect concerns about future returns on equity.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are relatively contained given Edwards' fortress balance sheet, but several warning signs merit attention. The debt-to-equity ratio of 0.068 and current ratio of 3.72 indicate minimal leverage and ample liquidity, yet Q1 2026 free cash flow turned negative at -$21.1 million due to a $501.5 million working capital outflow, a sharp reversal from $573.7 million in Q3 2025. Net margin declined to 23.1% in Q1 2026 from 25.3% in Q1 2025, and trailing EPS of $0.02 is distorted by one-time items, including a $279.9 million other expense in Q4 2025 that caused net income to collapse to $91.2 million. Revenue concentration is a key vulnerability: Transcatheter Heart Valves accounted for 72.6% of Q1 2026 revenue, meaning any slowdown in TAVR adoption or competitive encroachment would have an outsized impact on overall results.
Market and competitive risks are significant given EW's premium valuation and recent underperformance. The stock trades at 46.3x trailing PE and 33.3x EV/EBITDA, well above the medical device industry average of 20-30x, leaving it exposed to multiple compression if growth disappoints. EW has underperformed the S&P 500 by 8.27% over the past month and 8.07% over the past year, with a 1-month decline of 9.33% contrasting sharply with the broader market's -1.06% decline. The beta of 0.852 indicates lower volatility than the market, but this also means EW may lag in sharp rallies. Competitive threats from other transcatheter valve manufacturers, regulatory hurdles, and potential changes to Medicare reimbursement policies represent ongoing risks. The recent news about the Medicare coverage proposal is a double-edged sword: while it represents a major catalyst, any delay or dilution of the proposal could trigger a sharp negative reaction.
The worst-case scenario would involve a combination of Medicare coverage expansion failing to materialize, slower-than-expected TAVR procedure growth, and competitive share loss, leading to a revenue growth deceleration below 10% and multiple compression toward the sector average. In this scenario, the stock could retest its 52-week low of $72.30, representing a 14.3% decline from the current price of $84.37. If the bear case fully plays out and the stock falls to the analyst low target of $84.00, that would be roughly flat, but a more severe scenario could see a drop to the 52-week low, implying a -14.3% loss. The maximum drawdown over the past period was -13.19%, suggesting that a decline of this magnitude is within the realm of historical experience. Investors should be prepared for a potential 15-20% drawdown if the primary catalyst disappoints.
FAQ
The most severe risk is the potential delay or dilution of the Medicare coverage expansion, which is a key catalyst for the stock. If this proposal fails to materialize, the stock could lose a significant portion of its upside potential. Second, revenue concentration in the THV franchise (72.6% of Q1 2026 revenue) means any competitive disruption or slower TAVR adoption would disproportionately impact the company. Third, the premium valuation (46.3x trailing PE) leaves little room for error, and any earnings miss or growth deceleration could trigger a sharp multiple compression. Fourth, financial risks include negative Q1 2026 free cash flow of -$21.1 million and a $501.5 million working capital outflow, which, if sustained, could pressure the balance sheet. Finally, macro risks such as healthcare sector rotation and interest rate changes could affect the stock, though its beta of 0.852 indicates lower volatility than the broader market.
Our 12-month forecast for EW includes three scenarios. The bull case (30% probability) targets $100-$110, driven by successful Medicare coverage expansion and accelerating revenue growth above 18%. The base case (50% probability) targets $95-$105, assuming steady mid-teens revenue growth and moderate tailwinds from the Medicare proposal. The bear case (20% probability) targets $72-$84, reflecting a delay in the Medicare expansion, revenue growth decelerating below 10%, and multiple compression. The base case is the most likely, with the key assumption that revenue growth remains in the 14-17% range and the Medicare coverage expansion is implemented with minor modifications. The analyst consensus average target of $100.96 aligns closely with our base case.
EW's valuation is mixed depending on the metric. The trailing PE of 46.3x is well above the medical device industry average of 20-30x, suggesting a premium valuation. However, the forward PE of 25.0x is more reasonable and roughly in line with the higher end of the sector range, reflecting expected earnings growth. The PS ratio of 8.22x and EV/EBITDA of 33.3x are also premium multiples. On a price-to-book basis, the 4.82x ratio is near the lower end of its five-year range (4.1x to 13.9x), indicating the stock may be undervalued relative to its own history. The market appears to be pricing in significant growth, particularly from the TAVR franchise and the potential Medicare coverage expansion. If these catalysts materialize, the premium valuation is justified; if not, the stock could face multiple compression.
From a risk/reward perspective, EW appears attractive for long-term investors. The stock trades at $84.37, implying 19.7% upside to the analyst average target of $100.96, and even the lowest analyst target of $84.00 is essentially at the current price, suggesting limited downside according to the analyst community. The company's revenue grew 16.7% YoY in Q1 2026, the strongest in five quarters, and gross margins remain exceptionally high at 78.2%. However, the premium valuation (46.3x trailing PE) and recent price weakness (-9.33% in one month) mean the stock is not without risk. It is a good buy for investors with a medium to long-term horizon who believe in the TAVR growth story and the potential Medicare coverage expansion, but it may not be suitable for those seeking immediate upside or income.
EW is best suited for long-term investment given its growth stage, moderate volatility (beta of 0.852), and lack of dividend (payout ratio of 0). The company is in a strong growth phase, with revenue expanding at double-digit rates and a pipeline of innovative products in TMTT. The stock's recent underperformance and premium valuation suggest that short-term trading could be risky, as the stock is sensitive to news flow around the Medicare coverage expansion and quarterly earnings. A minimum holding period of 2-3 years is recommended to allow the TAVR growth story and the Medicare catalyst to fully play out. Income-focused investors may want to look elsewhere, as EW pays no dividend and is unlikely to initiate one given its focus on reinvesting in growth.
